Clinical trials: Desmoplastic Small Round Cell Tumor (DSRCT)
- Condition Desmoplastic Small Round Cell Tumor (DSRCT)
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Sarcoma
Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have…
- Trial name
- NCT00055952
- Testing
- exatecan mesylate
- Where
- 9 sites in United States, Canada
- Sponsor
- Daiichi Sankyo
Pediatric Solid Tumor, Pediatric Lymphoma
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment…
- Conditions
- Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG
- Trial name
- CLOVER-2 (NCT03478462)
- Testing
- CLR 131
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.
Peritoneal Cancer
Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum
A phase I study of Intraperitoneal Radioimmunotherapy with 131 I-omburtamab in patients >1 year of age with desmoplastic small round cell tumors and other solid tumors involving the peritoneum.
- Trial name
- NCT01099644
- Testing
- 131 I-8H9
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Y-mAbs Therapeutics
Refractory Desmoplastic Small Round Cell Tumors
Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors
An open-label, non-comparative study conducted to investigate the activity and safety of imatinib mesylate in refractory desmoplastic small round cell tumors expressing PDGF-R.
- Trial name
- NCT00417807
- Testing
- Imatinib mesilate
- Where
- 8 sites in Italy
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals